Company Profile
Arrowhead Pharmaceuticals
— An RNAi biotech that funded itself by licensing its TRiM platform to major companies and won approval for its first medicine in 2025
Arrowhead PharmaceuticalssiRNA (RNA )Biotech REDEMPLO (REDzasiran) was approved in the United States in November 2025. The majority of US$8,945 million net sales for the 20 year ended September 2025Income from partners such as SareptaComment In this article, we will organize the company's delivery technology "TRiM" and the company's own siRNA original medicine factory, and the management form that connects the funds in cooperation with the following information.
- Arrowhead in 30 seconds and standing position in drug discovery and DDS
- About logo and company name
- Where is this company in the world of drug discovery and DDS?
- Company size
- Drug discovery and DDS resources
- Past Initiatives
- Future plans
- What is DDS?
- Collaboration mapping of drug discovery and DDS
- Technologies, Products and Services
- The risk of this company
- Glossary/Source/Ins ment and Source Response Table
1. Arrowhead in 30 seconds and standing position in drug discovery and DDS
(siRNA)In 2025, our first product was approved
ArrowheadClearly separate "drugs to sell themselves" and "drugs to obtain funds from other companies"10-K Candidates that do not sell in-house are introduced to such as Sarupta, Amgen, Takeda, GSK, Nov s, etc. Funds"Undiluted Funds" that turn to development and sales of original products such as REDEMPLOContact Us FactsHome ar US$82,945 million net sales for the 20 year ended September 20,25, accounted for US$6,96.8 million (approx.84.0%) with a contract with Tarepta. This paper's outlineHome This companyBiotech is a source of revenue for siRNA design and delivery technology.Now, our sales have just started.
2. Logo and company name
Arrowhead Japan Inc. is a trademark of Arrowhead Japan Inc. In this article, we do not reproduce the generated image,
SVG data with logo embedded on the official website pageimg/arrowhead_logo.svg Contact Us
Note: Corporate name Arrowhead Pharmaceuticals, Inc.Home In Japanese, it is written as "Allow Head". Financial ResultsEnd of September"2025" refers to October 2024 - September 2025. Group companies may become contractual parties such as Visirna The eutics of consolidated subsidiaries (various entity).
Official Site:https://arrowheadpharma.com/3. Where is this company in the world of drug discovery and DDS?
TypeBiotech (siRNA)Comment 10-K explains the company’s drug “remoting and treating the cause gene of the disease”, RNA is caused by a wide range of RNA chemistry and delivery methods. FactsHome Delivery CenterTRiM（Targeted RNAi Molecule）siRNA Home7 Cells10-K is written when siRNA is delivered to FactsHome The mechanism of siRNA is handled by the technical commentary "nucleic acid medicine" of this series and the distribution to the tissue is "DDS and targeting".
4. Company Scope
| Indicators (US Accounting Standards, US Dollars) | FY2024 | FY2025 | October 2025 - June 2026 |
|---|---|---|---|
| Sales | 3.6 | 829.4 | 413.0 |
| Affiliated and licensed income | ― | 829.4 | 409.5 |
| R&D expenses | 505.9 | 607.2 | 548.7 |
| Net income and loss attributable to our shareholders | △599.5 | △1.6 | △296.2 |
Sales breakdown for the 20 year ending September 2025 is $696.8 million, $30 million, $2.6 million, $2.6 million, and $2.6 million. This article does not confirm the breakdown for the 20 year ending September 2024.
Our employees711 people(As of September 30, 2013) FactsHome As of June 30, 2026, the fund was $5,480 million in cash, etc. FactsHome Remains 、ing affiliation and licensing revenues (mainly the product sales of REDEMPLO) of US$4,302 million in sales from October 2025 to June 2026. This paper's outline。
The net income for the 20 year ending September 2025 was almost equivalent (USD 16 million), because the monthly contract fee of USD 5 billion was recorded in revenue, It is not possible to sell productsHome From October 2025 to June 2026, it is a deficit of US$2,620 million again Facts。
5. Drug discovery and DDS resources
| Resource Types | ation | |
|---|---|---|
| Person: Research Center | Research Institute of Madison, San Diego and Wisconsin (over 250,000 square feet). Data science using AI that analyzes genetics database, oligonucleotide, peptide, antibodies, and low s | Facts |
| Person: | 711 (as of September 30, 2025) Most clinical trials are CRO, some manufacturing is outsourced to contract manufacturers | Facts |
| Gold: R&D expenses | US$6,716 million (FY2025) US$3,757 million (57%) | Facts |
| Gold: Manufacturing Equipment | GMP Oligonucleotide plant and development and analysis lab (operational in August 2024 and expanded to the first quarter of FY2025) The size and scale of the facility that can produce hundreds of kilograms of GMP original drugs per year. No capital investment | Facts |
| External: Funding | Issued US$5 billion bonded turm loan frame with Sixth Street (August 2024), sale of olpasiran royalty to Royalty Pharma (November 2022), October 2025 - June 2026 | Facts |
| External: Investment and Acquisition | Invested in siRNA therapeutics using the eutectic method. Company of drug discovery and DDS | Facts |
| Graduate School | Leased from Wisconsin National Primate Research Center Madison Research Institute | Facts |
| Public Funds | Government Research Grants | Not specified |
6. Past Initiatives
| Time | Home | The meaning of drug discovery and DDS |
|---|---|---|
| September 2016 | oled olpasiran to Amgen (a) | large candidates for cardio |
| October 2018 | Candidate of hepatitis B (JNJ-3989) Moved to GSK in December 2023 | In ious Diseases |
| October 2020 | Joint development agreement with Takeda and fazirsiran (alpha1-anti-tripsin deficiency liver disease). U.S. divides profits 50 to 50 | Type of joint development and joint sales |
| November 2021 | GSK derives ARO-HSD (fat hepatitis) | Conduction in Liver Disease |
| November 2022 | Sell olpasiran royalty to Royalty Pharma | Cash future income forward |
| August 2024 | The GMP factory in Verona has obtained permission. Sixth Street | To manufacture original medicine |
| November 2024 | Comprehensive Partnership with Sarepta for Rare Diseases in Muscle, Central and LungsHome In February 2025, the contract pays $5 billion and receives $35 billion in stock investment | Large contracts evaluated by delivery technology outside the liver |
| August 2025 | Visirna sells the rights of Casazasiran in the Chinese region to Sanofi. Partnered with ARO-SNCA such as Nov)s and Parkinson's disease (US$2 billion) | Brain delivery |
| November 2025 | REDEMPLO ()zasiran) approved by the United States(Family hyperchromicemia syndrome). Milestone from Sarepta to US$2 Billion | First company product |
| December 2025 | Sarepta and Clinical Materials Manufacturing Agreement | Production for partners at our own factory |
| October 2025 - June 2026 | REDEMPLO approved in Europe, China, Canada, and Australia. ARO-DIMER-PA, which suppresses two genes with one genetic modification, is in clinical trials. | Clinical verification of two targets in one begins |
| May 2026 | ARO-PNPLA3, at the clinical stage in Madrigal, is being tested worldwide ($25 million, milestone up to $97,500). | Candidates for clinical stages |
| ending June 2026 | Phase III SHASTA-3 and SHASTA-4 of severe hypertriglyceridemia (sHTG) achieved the main evaluation item | A foothold of increasing adaptation to diseases with a large number of patients |
Clinical Trials: PALISADE (REDEMPLO)
This test was based on US approval in November 2025. The number is quoted from the US attachment,Does not recommend specific treatment Facts。
| Test name | PALISADE(NCT05089084) |
| Adults of familial hypercholesterolemia, which continues to be treated with low-fat diets, confirmed or clinically diagnosed with genes | |
| Dosage | REDEMPLO 25mg per 3 months 4 times subcutaneous injection (26 cases) vs placebo (25 cases), 12 months |
| Main evaluation items | Change rate of triglyceride after 10 months |
| Result | The median difference between placebo is -58.7% (95% confidence interval -89.6 - 27.9) |
7. Future plans
sHTGDiseases with a large number of patientsIt is said that it is planning to increase sales system step by step Undetermined / FutureHome The main items under development are:Not confirmed。
| Products | Stage | ||
|---|---|---|---|
| plozasiran（sHTG） | Severe hypertriglyceridemia | Developed (Part III SHASTA-3, 4, 5, MUIR-3). Breakthrough Therapy in the United States | Undetermined / Future |
| zodasiran | Families hypercholesterolemia | Developed (Part III Yosemite, completed in 70 cases) | Undetermined / Future |
| ARO-DIMER-PA | Mixed lipid dysfunction (at the same time suppressing PCSK9 and APOC3) | Development (Part I/IIa) | Undetermined / Future |
| ARO-MAPT | Tauopathies such as Alzheimer's disease | Development (Part I/IIa) | Undetermined / Future |
| ARO-DM1（SRP-1003） | Type 1 dy phy Sarepta | Under development (phase I/II) | Undetermined / Future |
None of the following are listed in the primary information Undetermined / Future。
SHASTA-3・4 resultsAt the time of evaluation(10-Q summary does not contain any values)/ sHTGPeriod of application and approval/TRiM7 Cell BreakdownSorry, this entry is only available in Japanese. Verona PlantOccupancy rate and capital investmentThis article does not use media and analysts.
8. What is this company aiming for drug discovery and DDS?
This includes parts that the company does not directly state.Range of the range that can be read from primary informationand write with the basis.
| Read | Primary Information | |
|---|---|---|
| Cardio and MetabolismIn-house salesRare diseases of muscles and nervesLeave it to a professional companyBusiness | REDEMPOZ・zodan develops in-house, targeting muscle and central nervous system diseases such as Sarepta, Parkinson's disease | |
| Different of deliveryOutside the liverHome | 10-K indicates that RNAi must aim for non-liver organs to demonstrate true power. Sarepta・Nov's s contracts target muscle and central nervous system | Facts |
| Make original medicine yourselfBe part of the competitiveness | We have hundreds of kg of GMP factory per year, and we have signed a manufacturing supply contract with Garepta. | |
| Multiple genes in oneProceed to design that suppresses | ARO-DIMER-PA is the first clinical candidate to target two genes in one genetic modification. | Facts |
10-K As Advantages Of TRiM Base"Manufacturing is simple and costly."Contact Us FactsHome In addition, we have explained that we can manufacture hundreds of kg of GMP original drugs per year. FactsHome Since REDEMPLO uses 25 mg every 3 months, the active ingredient per serving is 100 mg. If you can make 100kg per year, it is simple calculation.About 1 million yearsnot considered losses in preparation or quality testing) This paper's outlineHome This is not necessary for FCS of rare diseases.sHTG-like disease and partner-oriented manufacturing investmentRead Undetermined / Future。
9. Collaboration mapping of drug discovery and DDS
10. Technologies, Products and Services
TRiM base of Arrowhead according to 10-K"Strengthening target ligand", "Chemical linker", "Structure to improve drug delivery", "SRNActuated siRNA for each array"The design concept that combines four elements for each candidate FactsHome "TRiM" explains that it aims to improve safety by simplifying manufacturing, reducing costs and reducing metabolic properties.
| Products & Technologies | ||
|---|---|---|
| REDEMPLO（plozasiran） | siRNA dissolving APOC3 mRNA.。e ligands with three GalNAc residues to hepatocellular cells. 25mg per 3 months subcutaneous injection. Approved in the U.S., Europe, China, Canada, and Australia (Family hyperchromicemia syndrome) | Facts |
| TRiM Base | ligand binding siRNA delivery. The company explains that it is delivered to seven cells now | Facts |
| Contract manufacturing service | Manufacture supply agreement with Sarepta to supply clinical materials to our company | Facts |
| Patent | Issued about 643 (including 404 RNAi trigger s, 159 targeted compounds), about 883 applications | Facts |
REDEMPLO Attachments 2′ Place of Revos in Casazasiran(2′F) or metoxy (2′O-Me)Qualified and multiple chainsHomeIt is written that it contains. formula11 slices, 7 s, 43 s FactsHome Compared to antis、 nucleic acid (20、rus, 13-19、) seen in this series of ionis articles siRNALess perilin, instead of 2′ qualified to prevent decompositionI know This paper's outlineHome 2′F・2′O-Me) of Hos) Amidaito (Composition Unit)Syn and binding of GalNAc ligands, link two chains separatelyAnnealingThe process is added. Our factory has hundreds of kg per year.Is it possible to secure stable in kg units?It is the problem of the supply network and the front side Undetermined / Future。
11. Risks that this company has
| Risks | ||
|---|---|---|
| Dependency on partner income | ar.0% of sales for the 20 year ending September 2025 signed with Tarepta. The tie-up income can be shaken greatly in the time of temporary money or milestone | This paper's outline |
| Red and debt | Net loss from October 2025 to June 2026 USD 259.62 billion. Sixth Street’s financing and convertible bonds of $7 billion, and 10-K’s financing contracts are risked as risk | Facts |
| Launch of our own sales | REDEMPLO's product sales will be around $350 million from October 2025 to June 2026. | This paper's outline |
| Same target compet | Ionis TRYNGOLZA (olezarsen, antisense nucleic acid targeting the same APOC3) obtained US approval in sHTG in June 2026 | Facts |
| Royalty | Royalty Pharma receives olpasiran's loyalty. Even if Amgen succeeds, it is limited to Milestone (up to US$485 million remaining) | Facts |
| Demonstration of delivery outside the liver | Candidates for muscle and central nervous system are in phase I/II and not approved | Undetermined / Future |
12. Glossary
- siRNA
- Short two-strand RNA that causes RNA . Dissolve target mRNA and prevent protein from being created.
- TRiM
- Targeted RNAi Mole。e. A design that connects targeted ligands to siRNA and cuts off excess structures on the base of the delivery of Arrowhead.
- GalNAc
- N-acetyl galactosamine. Deliver siRNA to the liver with three ligands in sugar that binds to the receptor of liver cells.
- APOC3
- Apolipane Pak C-III. Protein made in the liver that slows down the decomposition and removal of neutral fats (triacylglycerides).
- Families High Chiro Micron Blood Syndrome (FCS)
- Genetic rare diseases that cannot decompose neutral fat, and blood triacylglycerides are high.
- Severe hypertriacylglyceridemia (sHTG)
- Blood triacylglyceride levels exceed 500mg/dL. More patients than FCS
- Sale of Royalty
- financing to sell the rights of royalty that should be received in the future to the investment company and obtain cash that has been previously received.
- GMP
- Pharmaceutical manufacturing and quality control standards. Raw materials and preparations given to humans must be made under GMP.
Concept diagram of AI generation13. Source
- Arrowhead Pharmaceuticals Form 10K for the) year ended September 30, 2025 Business overview, TRiM foundation, affiliation content, facility (including the Verona GMP factory), employee, patent, sales and R&D expenses, U.S. approval and loan agreement of REDEMPLO. https://www.sec.gov/Archives/edgar/data/879407/000087940725000029/arwr-20250930.htm
- Arrowhead Pharmaceuticals Form 10-Q for the quarterly period ended June 30, 2026 Oct. 2025 - Jun. 2026 Contract with sales, research and development costs, net income, Nov。s, Madrigal, and Sarepta, REDEMPLO approval, SHASTA-3, 4, YOUSEMITE, ARO-DIMER-PA, funding, and funding. https://www.sec.gov/Archives/edgar/data/879407/000087940726000057/arwr-20260630.htm
- National Library of Medicine DailyMed REDEMPLO (。zasiran) US attachment. Design and results of GalNAc-binding siRNA structure, chemical modification, 。 formula, and PALISADE test, and usage. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7fd37993-f85a-4af1-8bbe-133299f226ed
- Ionis Pharmaceuticals TRYNGOLZA (olezarsen) approved by the FDA ... in patients with hypertri eridemia (June 24, 2026). U.S. approval in sHTG of targeting the same APOC3. https://www.sec.gov/Archives/edgar/data/874015/000114036126026232/ef20076807_ex99-1.htm
- Arrowhead Pharmaceuticals Official website (for confirmation of company profile and logo) https://arrowheadpharma.com/
14. Response table of claims and sources
| Content | ||
|---|---|---|
| Official name, Delaware, head office location, Nasdaq listed, end of September | Facts | Source 1 https://www.sec.gov/Archives/edgar/data/879407/000087940725000029/arwr-20250930.htm |
| 18 clinical phases of the policy that leads out candidates that do not sell in-house, and “undiluted funds” | Facts | Source 1 https://www.sec.gov/Archives/edgar/data/879407/000087940725000029/arwr-20250930.htm |
| Net sales and breakdown, R&D expenses and breakdown, net income | Facts | Source 1 https://www.sec.gov/Archives/edgar/data/879407/000087940725000029/arwr-20250930.htm |
| Sales, tie-up income, R&D expenses, net income, and hand funds from October 2025 to June 2026 | Facts | Source 2 https://www.sec.gov/Archives/edgar/data/879407/000087940726000057/arwr-20260630.htm |
| 711 employees, research bases, Velona GMP factory (about 300,000 square feet, hundreds of kg per year), suppliers of primate testing, patents | Facts | Source 1 https://www.sec.gov/Archives/edgar/data/879407/000087940725000029/arwr-20250930.htm |
| Description of TRiM base, 7 kinds of cells, need to aim outside the liver | Facts | Source 1 https://www.sec.gov/Archives/edgar/data/879407/000087940725000029/arwr-20250930.htm |
| Amgen・Janssen/GSK・Takeda・Royalty Pharma・Sarepta・Sanofi(Visirna)・Nov)s・Sixth Street | Facts | Source 1 https://www.sec.gov/Archives/edgar/data/879407/000087940725000029/arwr-20250930.htm |
| REDEMPLO US Approval (November 18, 2025) | Facts | Source 1 https://www.sec.gov/Archives/edgar/data/879407/000087940725000029/arwr-20250930.htm |
| $2 billion, $2 billion from Nov's, $2 billion from Sarepta, $2 billion, $2 billion, $2 billion, $2 billion, $2 billion, $2 billion, $2 billion, $2 billion | Facts | Source 2 https://www.sec.gov/Archives/edgar/data/879407/000087940726000057/arwr-20260630.htm |
| REDEMPLO structure (GalNAc, 2′F・2′O-Me, Phospho,), formula), usage, design and results of PALISADE trials | Facts | Source 3 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7fd37993-f85a-4af1-8bbe-133299f226ed |
| Ionis TRYNGOLZA approved by sHTG (June 2026) | Facts | Source 4 https://www.sec.gov/Archives/edgar/data/874015/000114036126026232/ef20076807_ex99-1.htm |
| Sarepta is about84.0% of sales, about $3 million of sales of REDEMPLO, about 1 million years at 100 kg per year, compared with ASO | This paper's outline | This document is calculated from the number of source 1, 2, and 3 (premises in the body) |
| Classification of type 3 (pharmaceu) company / drug discovery biotech / contract development manufacturing / research) | This paper's outline | This article. Company name is an example from the company of this series. |
| Planning for additional application with sHTG, expected completion of YOSEMITE, and step-by-step expansion of sales system | Undetermined / Future | Source 1 and 2. Not a company plan https://www.sec.gov/Archives/edgar/data/879407/000087940726000057/arwr-20260630.htm |
| As of SHASTA-3 and 4, the application and approval period, the breakdown of seven cells, the occupancy and investment of the Velona plant, the establishment year | Undetermined / Future | I was unable to confirm this article in Sources 1 and 2. The term 'dewa' does not appear in this article. |
| Cardio and Metabolism are the rare diseases of the body, muscles and nerves. | Interpre of this paper from the tie-up structure of Source 1 and 2 | |
| sHTG and sHTG are looking forward to investing in manufacturing for partners. | Interpre of this paper from the description of the factory and production supply contract of Source 1 and 2 | |
| Issues of supply network to secure special raw materials in kg | Explanation of this article from the description of source 1 and 3 |
Last Updated:September 26, 2026/Troy Technical
The number of this paper is based on the statutory disclosure document (Form 10-K・10-Q) submitted by the US Securities and Exchange Commission (SEC) and the US attachment (DailyMed). Ionis’s SEC submission documents confirm the approval of the compet . We do not use estimates and media-based numbers of survey companies. The "、ulation" section is an interpretation that the article reads from the primary information and is not an announcement of the company. This article is not intended for medical advice, but does not recommend the use of certain drugs.